Vikram Mavinkurve
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Melanoma and MAPK Pathways, Nanoplatforms for cancer theranostics
Most-Cited Works
- → Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate(2017)74 cited
- → Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses(2014)54 cited
- → A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma(2020)43 cited
- → USP18 as a novel regulator of PD-1 and IFNAR1-mediated immune dysfunction (IRM11P.629)(2015)1 cited
- → Abstract 4008: Pegylated liposomal alendronate: The impact of the drug cargo on carrier-induced immune modulation(2016)1 cited
- → Supplemental Methods from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma(2023)
- → Data from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma(2023)
- → Supplemental Figure 3 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma(2023)
- → Supplemental Figure 1 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma(2023)
- → Supplemental Table 4 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma(2023)